ST Manfu: HW091077 has entered Phase II clinical trial research.

Announcement of ST Fuhui Corporation: Recently, its wholly-owned subsidiary Hubei Biomedical Industry Technology Research Institute Co., Ltd. publicly disclosed the registration information of the phase II clinical trial of HW091077 tablets on the drug clinical trial registration and information disclosure platform of the National Medical Products Administration.